To enhance U.S. sterile fill-finish contract manufacturing services to meet growing demand for prefilled syringes and cartridges that support patient-friendly administration of biologics. Read More >>
The upgrade includes a transition to a fully closed system designed to strengthen process and product integrity while minimizing microbiological risk across all stages of production.
Charles City expansion will add a new API plant with 140,000 liters of capacity and $30M expansion in Milan will add new analytical development and process R&D capabilities.
